2007
DOI: 10.1016/j.ctrv.2006.11.001
|View full text |Cite
|
Sign up to set email alerts
|

Pseudomyxoma peritonei

Abstract: Pseudomyxoma peritonei (PMP) is a rare condition, which is known for its high mortality when not treated properly. The first step to improve prognosis of these patients is to recognize this clinical syndrome preferably in an early stage. Knowledge of pathogenesis and common diagnostic tools is essential in this regard. Treatment strategy for PMP should pursue complete cytoreduction and prevention of recurrence or progression. Combined modality treatment, consisting of cytoreductive surgery with hyperthermic in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
67
0
4

Year Published

2010
2010
2020
2020

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 69 publications
(72 citation statements)
references
References 58 publications
1
67
0
4
Order By: Relevance
“…Favorable results with combined modality treatment have been achieved for patients with benign disease (DPAM) and complete cytoreduction, with 5-and 10-year survival rates of approximately 75%-100% and 68%, respectively [9,10,41]. However, patients with malignant disease (PMCA) or intermediate disease (PMCA-I) showed a significantly worse prognosis, with 5-and 10-year survival rates, respectively, of 50% and 21% for PMCA-I and 14% and 3% for PMCA [9].…”
Section: Management Of Gastrointestinal Mucinous Adenocarcinomas Withmentioning
confidence: 99%
See 2 more Smart Citations
“…Favorable results with combined modality treatment have been achieved for patients with benign disease (DPAM) and complete cytoreduction, with 5-and 10-year survival rates of approximately 75%-100% and 68%, respectively [9,10,41]. However, patients with malignant disease (PMCA) or intermediate disease (PMCA-I) showed a significantly worse prognosis, with 5-and 10-year survival rates, respectively, of 50% and 21% for PMCA-I and 14% and 3% for PMCA [9].…”
Section: Management Of Gastrointestinal Mucinous Adenocarcinomas Withmentioning
confidence: 99%
“…It is a locoregional disease within the abdomen, characterized by mucinous tumor on peritoneal surfaces producing excessive amounts of mucinous ascites [10]. The mucinous feature in PMP is mucinous ascites and not intracellular mucin accumulation in tumor cells.…”
Section: Gastrointestinal Mucinous Adenocarcinoma Pmpmentioning
confidence: 99%
See 1 more Smart Citation
“…However, conclusions cannot be drawn from ultra-sonography alone since the mucenous ascitis resembles free peritoneal fluid. 10 Computed tomography shows higher densities of collections (mucinous ascites) compared to nonmucinous collections, which is characteristic pattern of mucinous accumulation and the extent of disease for preoperative planning and prognostic purposes.…”
Section: Discussionmentioning
confidence: 99%
“…Sugarbaker reported curative treatment of malignant PMP with aggressive cyto-reductive surgery and adjuvant intraperitoneal chemotherapy [10]. Surgical de-bulking is the standard treatment, but combined modality treatment, consisting of aggressive peritonectomy with intra-operative hyperthemic intra-peritoneal chemotherapy is the new recommended standard approach [11].…”
Section: Discussionmentioning
confidence: 99%